q&more
My watch list
my.chemie.de  
Login  

Author

Prof. Dr. Theo Dingermann

Johann Wolfgang Goethe-Universität Frankfurt (Main), Institut für Pharmazeutische Biologie

Prof. Dr. Theo Dingermann

Theodor Dingermann, born 1948, studied pharmacy in Erlangen ­and received his doctor title in 1980 to become Dr. rer. nat. In 1990 he was offered the C4 professorship at the Institute for Pharmaceutical Biology, University of Frankfurt.  From 2000 to 2004 he was President of the German Pharmaceutical Society. Further, from 1998 to 2000 he was Vice-president of the Goethe University, Frankfurt/Main. Dingermann is involved in many committees. Among other things, he is a member of the Scientific Advisory Committee of the Perso­nalized Medicine Foundation, Speaker of the Scientific Advisory Committee of the Federal Chamber of Pharmacists and Biotechnology Representative for the state of Hessen. He is chief editor of the scientific journal “DIE PHARMAZIE” (“The Pharmacy”), editor of the magazine “PHARMAZIE IN UNSERER ZEIT” (“Pharmacy in our Time” and member of the Editorial Board of the PHARMAZEUTISCHEN ZEITUNG (PZ) (“Pharmaceutical Journal”). In 2007 he received the 1822 University Award for excellent teaching (awarded: € 15,000), in 2009 was elected for „Professor of the Year“ in the category Natural Sciences and Medicine, and received in 2010 the Carl-Mannich-Medal of the German Pharmaceutical Society.

Facts, background information, dossiers

Other articles by this author

All articles

Paradigm shift

What would medicine be without drugs? But are these drugs being used optimally today? Not at all, as we now know thanks to the findings of molecular medicine. Because for the use of (…)

Why biosimilars and not biogenerics?

Medicines produced using genetic techniques have existed since 2006, called “similar biological medicinal products” or “biosimilars”. Until a year ago, this was a fairly low-profile group (…)

More about Uni Frankfurt am Main

  • News

    Frederick W. Alt and David G. Schatz to be awarded the 2023 Paul Ehrlich and Ludwig Darmstaedter Prize

    Immunologists Frederick W. Alt (73) of Harvard Medical School and David G. Schatz (64) of Yale School of Medicine are to receive the 2023 Paul Ehrlich and Ludwig Darmstaedter Prize, as the Scientific Council of the Paul Ehrlich Foundation announced. The two researchers are being acknowledge ... more

    How do killer T cells know where danger is coming from?

    How do killer T cells recognise cells in the body that have been infected by viruses? Matter foreign to the body is presented on the surface of these cells as antigens that act as a kind of road sign. A network of accessory proteins – the chaperones – ensure that this sign retains its stabi ... more

    Laboratory study: effect of antibodies against omicron variants BA.1 and BA.2 wears off quickly

    The omicron variants BA.1 and BA.2 of the SARS-CoV-2 virus, which are dominant from about December to April, can undermine the protection against infection offered by vaccinations or survived infections after only three months. This is shown by a study from Frankfurt under the leadership of ... more

  • q&more articles

    From feast to famine and back – no problem for bacteria

    Bacteria are true survivors. In the course of evolution, they have developed numerous strategies to adapt to rapidly changing, uncertain environmental conditions. Their metabolism is much more sophisticated than that of human beings. Within minutes they can regulate their gene expression an ... more

    Why biosimilars and not biogenerics?

    Medicines produced using genetic techniques have existed since 2006, called “similar biological medicinal products” or “biosimilars”. Until a year ago, this was a fairly low-profile group, even in expert circles. This has all changed now, however, with the recent licensing of the first bios ... more

    Paradigm shift

    What would medicine be without drugs? But are these drugs being used optimally today? Not at all, as we now know thanks to the findings of molecular medicine. Because for the use of these drugs, it is important to observe two aspects: the disease and the patient. Only slowly is it becom ... more

  • Authors

    Prof. Dr. Claudia Büchel

    Claudia Büchel, born in 1962, studied biology at the University of Mainz, where she also received her doctorate and, in 2001, the qualification to teach plant physiology. After a postdoctoral research period at the Biological Research Centre, Szeged, she worked for four years as a research ... more

    Prof. Dr. Jörg Soppa

    Jörg Soppa, born in 1958, studied biochemistry in Tübingen and then went on to do his doctorate at the Max Planck Institute of Biochemistry in Martinsried near Munich. In 1990 he established his own research group there and held courses at the Institute of Genetics and Microbiology of Munic ... more

    Prof. Dr. Heinfried H. Radeke

    Heinfried H. Radeke studied medicine at the Hannover Medical School (MHH) and received his medical license in 1985. His Ph.D. thesis was recognized as the best research dissertation of 1986. After two years as an assistant physician at the Göttingen University Hospital, he began his career ... more

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by:

 

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE